23,367 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by CenterBook Partners LP

CenterBook Partners LP purchased a new position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 23,367 shares of the company's stock, valued at approximately $1,913,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PCVX. CIBC Asset Management Inc lifted its holdings in shares of Vaxcyte by 5.5% in the fourth quarter. CIBC Asset Management Inc now owns 3,307 shares of the company's stock worth $271,000 after buying an additional 171 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after purchasing an additional 260 shares in the last quarter. Catalyst Funds Management Pty Ltd increased its holdings in shares of Vaxcyte by 1.7% in the fourth quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock worth $1,506,000 after purchasing an additional 300 shares during the last quarter. Whipplewood Advisors LLC purchased a new stake in shares of Vaxcyte in the fourth quarter worth about $28,000. Finally, Blue Trust Inc. boosted its stake in Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after buying an additional 371 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Insider Activity

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $86.22, for a total value of $689,760.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at $17,735,022.90. This trade represents a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Teri Loxam sold 6,250 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now directly owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,250 shares of company stock worth $3,170,738. 3.10% of the stock is currently owned by company insiders.

Remove Ads

Analysts Set New Price Targets

PCVX has been the topic of several research reports. Needham & Company LLC restated a "buy" rating and issued a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. Bank of America reduced their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Guggenheim reissued a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, The Goldman Sachs Group decreased their price objective on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Vaxcyte presently has a consensus rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Stock Down 5.6 %

NASDAQ:PCVX traded down $1.81 during midday trading on Tuesday, hitting $30.23. The stock had a trading volume of 2,524,458 shares, compared to its average volume of 1,206,479. The stock has a 50-day moving average of $65.25 and a 200 day moving average of $84.98. The company has a market capitalization of $3.89 billion, a price-to-earnings ratio of -6.57 and a beta of 1.26. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. On average, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.